Domestic innovation drug companies are leading the fourth generation of EGFR target-to-drug research and development.

The fourth generation of EGFR targets is becoming a new research and development direction in the field of oncology treatment, mainly targeting the third generation of EGFR-TKI resistance treatment needs. The problem of resistance to medicines has been one of the most common mutations of EGFR targets, with a prevalence of about 20 per cent. In order to meet clinical needs, the fourth generation EGFAR targets are being actively developed by domestic innovation companies, while the third most advanced tube line in global R&D can be extended to 18-20 months, but it is not possible to completely avoid resistance. After about 10 months of use of the third generations of EGR-TKI treatments, some patients will be exposed to new resistance to EFR-09 and the second half of the 4-day phase of S-E-L-E-2 high demand for stimuli, while more than 50 per cent of the D-R-E4-L4 are found to be among the most vulnerable and less well developed in transnational countries.